Castleman Disease: Causes, Symptoms, and Treatment Options
Castleman disease is a rare and complex lymphatic system disorder. It is characterized by the abnormal proliferation of lymphoid cells in lymph nodes. This pathology was first described in 1956 by Dr. Benjamin Castleman. It manifests through a hyperactivation of the immune system, leading to a chronic state of inflammation in the body. Although not considered a malignant condition, Castleman disease can have a significant impact on patients’ quality of life. It requires a multidisciplinary therapeutic approach. Depending on its extent, the disease can be classified into two main forms: unicentric and multicentric. Each form has distinct clinical and prognostic characteristics. Understanding the pathogenic mechanisms, clinical manifestations, and available therapeutic options is essential for the optimal management of this rare condition.
What is Castleman Disease?
Castleman disease is a rare lymphoproliferative disorder. It is characterized by the abnormal growth of lymphoid tissue. This pathology affects the lymphatic system, a crucial component of the immune system. The lymphatic system is responsible for fighting infections and eliminating toxins from the body.
In essence, Castleman disease causes a hyperactivation of the immune system. This leads to a chronic state of inflammation that can affect multiple organs and systems.
Castleman Disease: Types and Classification
There are two main types of Castleman disease. Each has distinct characteristics and therapeutic approaches. Castleman disease unicentric (UCD) affects a single lymph node or a single region of the body. This is the more common form and is usually asymptomatic. It has a favorable prognosis following surgical treatment.
On the other hand, Castleman disease multicentric (MCD) involves multiple lymph nodes in different areas of the body. This form is more aggressive. It presents with systemic symptoms and requires a complex therapeutic approach.
Castleman Disease: Subtypes and Histopathological Aspects
MCD is subdivided into three subtypes: MCD idiopathic (of unknown cause), MCD associated with human herpesvirus 8 (HHV-8), and MCD associated with POEMS syndrome (a rare blood disorder). Histopathologically, Castleman disease can be classified into the hyaline-vascular type (most common, especially in the unicentric form) and the plasma cell type (rarer, primarily associated with the multicentric form).
Although not considered a cancerous disease, Castleman disease can progress to lymphoma in some cases. This requires careful monitoring and appropriate treatment. Understanding the nature and subtypes of this condition is crucial for establishing a personalized and effective therapeutic plan.
Causes and Risk Factors of Castleman Disease
The exact etiology of Castleman disease remains incompletely elucidated. Research has identified a series of potential factors involved in the onset of this rare condition.
Immune system dysregulation plays a central role in the pathogenesis of the disease. Abnormal and persistent immune system activation is considered a key factor in the development of symptomatology. Infection with human herpesvirus 8 (HHV-8) is closely associated with the multicentric form of Castleman disease. This is more frequent in individuals with HIV or compromised immune systems.
Castleman Disease: The Role of IL-6 and Genetic Mutations
Another important factor in the pathogenesis of Castleman disease is the excessive production of interleukin-6 (IL-6). This is an inflammatory protein frequently present in high quantities in affected patients. This overproduction of IL-6 contributes to lymphoid cell proliferation and the onset of the systemic symptoms characteristic of the disease. Certain genetic mutations can increase an individual’s susceptibility to developing Castleman disease. The exact mechanisms by which these influence the onset of the disease are not fully understood.
Regarding risk factors, age plays an important role in the distribution of Castleman disease types. The unicentric form occurs more frequently in young adults, aged between 30 and 40 years. The multicentric form predominantly affects individuals over 50 years of age. The male sex appears to be slightly more predisposed to developing the multicentric form.
Castleman Disease: Risk Factors and Implications
HIV infection is a significant risk factor for developing the HHV-8 associated multicentric form. This underscores the importance of screening and adequate management of HIV-positive patients. Immunodeficiencies, regardless of their cause, can favor the onset of Castleman disease. They disrupt the normal function of the immune system. Some studies suggest a possible link between exposure to certain environmental toxins and an increased risk of developing the disease. This association requires further investigation to be fully validated.
[cta_produs style=”style_1″ product=”51122″ image=”https://aronia-charlottenburg.com/wp-content/uploads/2025/02/Cauzele-si-factorii-de-risc-ai-bolii-Castleman.jpg”]
In the context of managing Castleman disease, special attention must be paid to the impact of nutritional factors and natural supplements on patients’ health. Regular consumption of foods with a high antioxidant profile, such as aronia and sea buckthorn, has been identified in numerous studies as a beneficial adjunct in supporting the immune system.
Castleman Disease: Benefits of Aronia and Sea Buckthorn
Aronia, due to its significant concentration of anthocyanins, vitamins, and polyphenols, is an excellent anti-inflammatory agent. It plays a crucial role in reducing chronic inflammation associated with various autoimmune and infectious diseases. Aronia juice, in particular, is easily integrated into the daily diet. It offers tangible benefits in improving immune function. It stimulates cytokine production and activates T lymphocytes, essential in the body’s defense. Studies suggest that aronia can help protect cells against virus-induced damage. This can have a positive impact on patients with HIV or other immunodeficiencies.
Sea buckthorn, with its high content of vitamin C and essential fatty acids, effectively complements the beneficial effects of aronia. It supports epithelial cell regeneration. It plays an important role in protecting the cardiovascular system. This can be particularly useful for patients with Castleman disease, who are often exposed to increased cardiovascular risks. Sea buckthorn juice, known for its immunostimulatory properties, can help strengthen the body’s immune barriers. Thus, it reduces the risk of secondary infections and chronic inflammation.
It is crucial to understand that the presence of one or more risk factors does not necessarily imply the development of Castleman disease. Many individuals with these risk factors will never develop this condition. Others, without known risk factors, may be diagnosed. This variability highlights the complexity of the disease. It requires an individualized approach in the evaluation and management of patients.
Symptoms of Castleman Disease
Photo credit: Shutterstock.com
The clinical manifestations of Castleman disease vary considerably depending on the type and extent of the condition. They can range from asymptomatic forms to severe clinical presentations.
In the case of Castleman disease unicentric (UCD), symptoms are often absent or minimal. The disease is frequently discovered incidentally during imaging investigations performed for other reasons. When present, UCD symptoms are usually localized. They may include the appearance of a painless mass in the affected area. Most commonly, this occurs in the chest, neck, or abdomen.
Castleman Disease: Symptoms of the Multicentric Form
In contrast, Castleman disease multicentric (MCD) is characterized by a more complex and systemic clinical picture. Symptoms frequently encountered in MCD include persistent or recurrent fever. Also, abundant night sweats, marked fatigue, and significant weight loss may occur. These manifestations are known as B symptoms. They are similar to those seen in lymphomas and other lymphoproliferative disorders.
Patients with MCD may also present with generalized lymphadenopathy. This is characterized by enlarged multiple lymph node groups. Hepatosplenomegaly is another common manifestation. It reflects the systemic involvement of the disease. In severe cases, peripheral edema, pleural or pericardial effusions may occur. These arise from fluid retention and increased vascular permeability induced by chronic inflammation.
Castleman Disease: Cutaneous and Gastrointestinal Manifestations
On the other hand, skin manifestations are diverse. They may include rashes, intense itching, or vasculitic lesions. For example, some patients develop polyneuropathy. This is characterized by muscle weakness and paresthesias in the extremities.
In forms associated with POEMS syndrome, endocrine changes may occur. These include diabetes mellitus or hypothyroidism. Gastrointestinal symptoms, such as nausea, vomiting, or diarrhea, are frequently reported. They are more significant in active phases of the disease. Persistent cough and shortness of breath may be present due to lung involvement or compression of the airways by enlarged lymph node masses.
It is important to remember that the intensity and combination of these symptoms can vary significantly from one patient to another. Some individuals may experience only a few mild symptoms. Others may experience severe manifestations that significantly affect their quality of life. Early recognition of these symptoms and prompt medical attention are essential. They help establish a correct diagnosis and initiate appropriate treatment.
Diagnosing Castleman Disease
Diagnosing Castleman disease is often a challenge for clinicians. This is due to the rarity of the condition and its nonspecific symptoms, which can mimic other pathologies. The diagnostic process involves a complex approach. It combines careful clinical evaluation with a series of specific paraclinical investigations.
The clinical examination is the first step in evaluating a patient suspected of having Castleman disease. At this stage, the doctor will conduct a detailed medical history. They will aim to identify characteristic symptoms and potential risk factors. Careful palpation of lymph node regions is essential. Abdominal examination to detect hepatosplenomegaly is also important.
Castleman Disease: Blood Tests and Imaging Studies
Blood tests play a crucial role in the diagnostic process. They can reveal suggestive changes such as anemia, thrombocytosis, or thrombocytopenia. They may also show an increase in erythrocyte sedimentation rate (ESR) and C-reactive protein. Determining interleukin-6 (IL-6) levels and other inflammatory markers can provide valuable information about disease activity. Imaging studies are indispensable for assessing the extent of the disease and guiding biopsy.
On the other hand, chest X-ray can reveal mediastinal or hilar adenopathy. Abdominal ultrasound is useful for evaluating internal organs and retroperitoneal lymph nodes. Computed tomography (CT) and magnetic resonance imaging (MRI) provide a detailed view of the distribution and size of the lesions. They are essential for staging the disease and planning treatment. In rare cases, positron emission tomography (PET-CT) may be used to assess the metabolic activity of the lesions.
Castleman Disease: Lymph Node Biopsy and Additional Tests
However, lymph node biopsy remains the gold standard for confirming the diagnosis of Castleman disease. Histopathological examination of the tissue collected can reveal characteristic changes. These include lymphoid follicle proliferation, germinal center hyperplasia, and increased vascularity between follicles. Depending on the histological type, a predominance of plasma cells or the characteristic hyaline-vascular appearance may be observed.
Furthermore, in some cases, additional tests may be necessary. These include testing for human herpesvirus 8 (HHV-8) infection, especially in cases of multicentric Castleman disease, and HIV testing. Immunohistochemistry can provide valuable information about the cell types involved. It can help differentiate Castleman disease from other lymphoproliferative disorders.
Finally, it is essential to understand that the diagnosis of Castleman disease requires a multidisciplinary approach. It involves close collaboration between clinicians, radiologists, and pathologists. Early and accurate diagnosis is crucial for initiating prompt and appropriate treatment. It is also essential for improving the prognosis of patients affected by this rare condition.
Treatment Options for Castleman Disease
The therapeutic approach to Castleman disease varies significantly depending on the type and severity of the condition. It requires a personalized strategy for each patient. The main treatment objectives include symptom control, reduction of systemic inflammation, and prevention of long-term complications.
For Castleman disease unicentric (UCD), surgical intervention is the first-line treatment. Complete removal of the affected lymph node leads to healing of the disease in most cases. It has an excellent success rate and a favorable long-term prognosis.
Castleman Disease: Radiotherapy and Systemic Approaches
In situations where complete surgical resection is not feasible, radiotherapy may be used as an alternative or adjuvant treatment. It can be effective in reducing tumor size and alleviating local symptoms.
The management of Castleman disease multicentric (MCD) is considerably more complex. It requires a systemic approach. Corticosteroids are frequently used as first-line treatment. They are effective for rapid inflammation control and relief of acute symptoms. They can be administered as monotherapy in mild cases or as part of a combination therapy regimen in more severe forms.
Castleman Disease: Immunotherapy and Targeted Therapies
In this context, immunotherapy has revolutionized the treatment of MCD in recent years. For example, siltuximab, a monoclonal antibody against IL-6, has demonstrated significant efficacy in controlling symptoms and reducing disease progression in patients with idiopathic MCD. In contrast, rituximab, a monoclonal antibody against CD20, is successfully used primarily in cases of MCD associated with HHV-8 or in combination with other therapies for refractory forms.
However, chemotherapy remains an important option for severe or treatment-refractory cases. Regimens based on cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or their variants are frequently used.
Castleman Disease: Stem Cell Transplant and Long-Term Management
In cases associated with HHV-8 infection, adding antiviral drugs such as ganciclovir may provide additional benefits. Targeted therapies, such as JAK inhibitors (e.g., ruxolitinib) or mTOR inhibitors (sirolimus), are being investigated in clinical trials. They may offer promising options for patients with refractory forms of the disease.
On the other hand, in severe cases of MCD that do not respond to conventional therapies, hematopoietic stem cell transplantation may be considered as a last-line option. Experience in this area remains limited.
Overall, the treatment of Castleman disease requires close monitoring and frequent adjustments of the therapeutic regimen. Treatment response can vary considerably among patients. Managing side effects and potential complications is an essential component of long-term care. Close collaboration between the patient and a multidisciplinary medical team is fundamental. It helps optimize therapeutic outcomes and improve the quality of life for individuals affected by this rare condition.
Complications and Prognosis in Castleman Disease
Castleman disease, particularly its multicentric form, can lead to a series of severe complications. These significantly affect the prognosis and quality of life of patients. Understanding these potential complications is essential for adequate disease management. It is also important for implementing preventive strategies.
One of the most concerning complications of Castleman disease is an increased risk of developing lymphoma or other lymphatic cancers. This malignant transformation is observed more frequently in cases of Castleman disease multicentric (MCD). It can be associated with persistent human herpesvirus 8 (HHV-8) infection. Close monitoring and periodic evaluations are crucial for early detection of this complication.
Castleman Disease: Opportunistic Infections and Multiple Organ Failure
Patients with Castleman disease, especially those with the multicentric form, have an increased risk of severe opportunistic infections. This is due to both the immune system dysfunction caused by the disease itself and the immunosuppressive effects of the treatments used. Infections can range from common bacterial infections to opportunistic fungal or viral infections. These can be potentially fatal in the absence of prompt and adequate management.
In advanced cases of MCD, multiple organ failure can occur. This is a severe complication. It results from persistent systemic inflammation and the direct effects of the disease on various systems and organs. Manifestations can include kidney, liver, respiratory, or heart failure. These often require intensive care and complex therapeutic interventions.
Castleman Disease: POEMS Syndrome and Hematologic Disorders
Concurrently, the development of POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) is another potential complication. This is more common in certain subtypes of MCD. This complex paraneoplastic syndrome can significantly impact the patient’s functionality. It requires a multidisciplinary therapeutic approach.
Severe anemia and other hematologic disorders are frequently encountered in Castleman disease. They may require repeated transfusions or other specific therapeutic interventions. These complications can significantly affect patients’ quality of life. They can increase the risk of morbidity and mortality.
Castleman Disease: Prognosis and Long-Term Management
Last but not least, the prognosis in Castleman disease varies considerably depending on the type and severity of the condition. For Castleman disease unicentric (UCD), the prognosis is generally excellent. Complete surgical removal of the affected lymph node usually leads to healing. Relapses do not occur, and patients can have a normal life expectancy.
In the case of MCD, the prognosis is more reserved. It depends on several factors, including response to treatment. It also depends on the presence of HHV-8 or HIV infection, the degree of vital organ involvement, the patient’s age, and general health status. Recent studies show that the 5-year survival rate for patients with MCD is approximately 65-75%. These figures have significantly improved in recent years due to new therapeutic options, especially targeted therapies and immunotherapy.
In other words, individual prognosis can vary considerably. Many individuals with Castleman disease, even in its more severe forms, can have a good quality of life. They can have long-term survival with adequate management. Close monitoring, adherence to treatment, and prompt management of complications are essential. They help optimize long-term outcomes.
Managing Daily Life with Castleman Disease
Photo credit: Shutterstock.com
Living with Castleman disease can be a significant challenge. It affects multiple aspects of daily life. However, by adopting appropriate disease management strategies and making lifestyle adjustments, quality of life can be improved. An optimal level of functionality can be maintained.
First and foremost, symptom management plays a crucial role in the daily lives of people with Castleman disease. Fatigue, one of the most common and debilitating symptoms, can be managed by careful planning of daily activities. Also, by including regular rest periods.
Castleman Disease: Diet and Hydration
Maintaining a balanced and nutritious diet is essential for supporting the immune system. It also helps manage the chronic inflammation associated with Castleman disease. Adequate intake of proteins, vitamins, and minerals can help combat anemia. It also improves overall health. Proper hydration is also crucial. It helps reduce inflammation and maintain optimal organ function.
To support the immune system and combat inflammation, you can include Aronia and Sea Buckthorn Juice 3L ECO in your diet. This is a 100% natural and organic product. It is rich in antioxidants and essential vitamins.
Castleman Disease: Stress Management and Clinical Monitoring
Stress, through its impact on the hypothalamic-pituitary-adrenal axis and the autonomic nervous system, can worsen the symptoms of Castleman disease. It can promote the excessive release of pro-inflammatory cytokines like IL-6. This can lead to increased systemic inflammation, fatigue, and other specific clinical manifestations. Therefore, practicing stress management techniques, such as mindfulness meditation, plays an important role. Not only in reducing cortisol levels but also in improving biological parameters associated with the inflammatory response. At the same time, these techniques can contribute to optimizing sleep quality and improving overall psychosomatic health.
Regular clinical monitoring is fundamental in the management of Castleman disease. Given the possibility of symptom progression or the occurrence of complications, periodic examinations are essential. These include complete blood count, inflammatory marker measurement (CRP, fibrinogen), and follow-up imaging. These can provide essential information about the disease’s evolution. Keeping a detailed symptom diary – including details such as severity, frequency, or circumstances of their onset – can facilitate precise communication with the medical team. It can also help in adapting the therapeutic plan in real-time.
Castleman Disease: Adapting Daily Activities and Psychosocial Support
Adapting daily activities to individual functional capacity is crucial. It helps prevent overexertion and maintain an acceptable quality of life. Strategies such as prioritizing essential tasks, avoiding overly strenuous activities, and planning rest during periods of low energy can be helpful. These are useful in effectively managing chronic fatigue. For professionally active individuals, implementing reasonable adjustments, such as reducing working hours or facilitating an ergonomic environment, can mitigate the risk of physical and emotional exhaustion.
Psychosocial support plays an essential role in the coping process. It has beneficial effects on patients’ quality of life. Rare disease support groups, by sharing experiences and practical strategies, can contribute to reducing feelings of isolation. They can also increase emotional resilience. Thus, a strong support network from family and friends can provide both emotional support and practical help in managing daily demands.
Castleman Disease: Education and Communication with the Medical Team
Ongoing patient education about Castleman disease, based on validated medical sources, is vital. It helps in active participation in the therapeutic decision-making process. Accessing up-to-date information on new therapies, clinical trials, or international recommendations contributes to optimizing treatment outcomes. It also helps in developing a sense of control over the disease. Open and frequent communication with the medical team remains essential. It helps clarify doubts and adjust therapeutic strategies according to the patient’s specific needs.
In conclusion, managing daily life with Castleman disease requires a holistic approach. This should encompass medical management, lifestyle adjustments, and psychosocial support. By implementing these strategies and maintaining a proactive attitude towards your health care, you can significantly improve your quality of life. You can also more effectively manage the challenges posed by this rare condition.
References:
Ehsan N, Zahra F. Castleman Disease, [Updated 2023 Apr 27], StatPearls [Internet], Treasure Island (FL): StatPearls Publishing; 2025 Jan-, https://www.ncbi.nlm.nih.gov/books/NBK576394/;
Castleman Disease, https://www.mayoclinic.org/diseases-conditions/castleman-disease/symptoms-causes/syc-20543017;
Castleman Disease, https://my.clevelandclinic.org/health/diseases/17920-castleman-disease
Photo credit: Shutterstock.com